Acute Myeloid Leukemia Clinical Trials in Houston, Texas

54 studies are recruiting for acute myeloid leukemia in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 3

  1. Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

    This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Source: FDA OOPD

    Stage
    Phase 1
    Ages
    18 and older
    Site
    M.D. Anderson Cancer Center, Department of Leukemia, Houston, Texas
    Locations
    2 in total
    Run by
    Montefiore Medical Center

    See if you can join NCT05986240 on ClinicalTrials.gov

  2. Study of REM-422 in Patients With AML or Higher Risk MDS

    The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    9 in total
    Run by
    Remix Therapeutics

    See if you can join NCT06297941 on ClinicalTrials.gov

  3. Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

    Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    5 in total
    Run by
    Vincerx Pharma, Inc.

    See if you can join NCT06034275 on ClinicalTrials.gov

  4. A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will be done i…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    3 in total
    Run by
    Edgewood Oncology Inc.

    See if you can join NCT04243785 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.